Biosimilar medicines - Multistakeholder Event

As for the past years, the objective will be to raise awareness towards all and highlight the potential of biosimilars in improving affordability and access to medicines.  Broadly speaking, the following sessions will take place:

• Ensuring biosimilar development and competition in Europe: where are we now?
  Confirmed speakers: IQVIA sharing the key findings of their yearly biosimilar competition report; Steffen Thirstrup (Chief Medical Officer EMA) for a regulatory perspective on biosimilar development; Leen De Vreese (Case Handler Officer DG COMP, European Commission) presenting the Competition Enforcement Report in the pharmaceutical sector (2018-2022)
• Promoting biosimilar uptake: current developments
  Confirmed speakers: Prof. MD Tore Kristian Kvien (Diakonhjemmet Hospital Oslo) with a keynote presentation on biosimilar use in the rheumatology field; as well as updates on different national biosimilar policies (including from Norway, Belgium and Portugal)
• AUGMENT: an EU4Health biosimilar capacity-building project
  The AUGMENT consortium, entailing the Austrian National Public Health Institute, the Polish Agency for HTA and Tariff System, Medical University of Sofia and NOVA University of Lisbon, will provide an introduction to the recently launched EU4Health project. The project aims to encourage biosimilar uptake through a comprehensive multistakeholder approach by generating evidence, enhancing knowledge, and building capacity. Participants are invited to attend the consortium's afternoon session, featuring engaging speakers and dynamic break-out discussions.

Registration

• To be able to attend online, please register, preferably by 22 November 2024

More information

• Agenda
• Privacy statement